Neratinib Shrank Brain Mets in Half of HER2+ Breast Cancer Patients

Video
Conference|ASCO Annual Meeting: Breast Cancer

This video examines results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients.

In this video, Rachel A. Freedman, MD, MPH, of the Dana-Farber Cancer Institute, discusses results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients.

Freedman presented the results of the study (abstract 1005) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
3 experts in this video
3 experts in this video
3 experts in this video
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
Related Content
Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

ONCOLOGY Staff
June 19th 2024
Article

Carey K. Anders, MD, spoke about updated findings in the HER2-positive breast cancer space, based on data from 2023 SABCS.

HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

Sara Hurvitz, MD
January 8th 2024
Podcast

Tucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.

Targeted Therapy Options for HER2+ Breast Cancer

Targeted Therapy Options for HER2+ Breast Cancer

ONCOLOGY Staff
January 13th 2024
Article

A Satellite Session, involving members from US Oncology, focused on treatment options for patients with HER2-positive metastatic breast cancer.

Oncology Peer Review On-The-Go: Paolo Tarantino, MD, and Sara Tolaney, MD, Review Data in the Treatment of Breast Cancer at 2022 ASCO

Oncology Peer Review On-The-Go: Paolo Tarantino, MD, and Sara Tolaney, MD, Review Data in the Treatment of Breast Cancer at 2022 ASCO

Paolo Tarantino, MD;Sara M. Tolaney, MD, MPH
July 5th 2022
Podcast

Paolo Tarantino, MD, and Sara M. Tolaney, MD, MPH, spoke with CancerNetwork® about highlights from 2022 ASCO in breast cancer research.

Combining tucatinib with ado-trastuzumab emtansine does not appear to result in any new safety signals in the treatment of those with locally advanced or metastatic HER2-positive breast cancer.

Tucatinib/T-DM1 Yields ‘Encouraging’ PFS in Unresectable HER2+ Breast Cancer

Russ Conroy
August 31st 2023
Article

Combining tucatinib with ado-trastuzumab emtansine does not appear to result in any new safety signals in the treatment of those with locally advanced or metastatic HER2-positive breast cancer.

Findings from the phase 3 DESTINY-Breast04 trial supported the approval of fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer in China.

Trastuzumab Deruxtecan Receives Chinese Approval in HER2-Low Breast Cancer

Hayley Virgil
July 15th 2023
Article

Findings from the phase 3 DESTINY-Breast04 trial supported the approval of fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer in China.